(Reuters) - NICE added that the drug should only be used once patients
had already lost the sight in one eye and also said it did not
recommend the use of rival drug Macugen made by OSI
Pharmaceuticals .
The draft guidence drew criticism from health campaigners
who said the decision would condemn 20,000 people a year to
blindness.
Read more at Reuters.com Government Filings News
had already lost the sight in one eye and also said it did not
recommend the use of rival drug Macugen made by OSI
Pharmaceuticals .
The draft guidence drew criticism from health campaigners
who said the decision would condemn 20,000 people a year to
blindness.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment